Abstract: The instant disclosure provides antibodies that specifically bind to T-cell immunoreceptor with Ig and ITIM domains (TIGIT) (e.g., human TIGIT) and antagonize TIGIT function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.

Abstract: The present application provides anti-VISTA constructs that bind to VISTA (e.g., anti-VISTA antibodies), nucleic acid molecules encoding an amino acid sequence of the anti-VISTA, vectors comprising the nucleic acid molecules, host cells containing the vectors, methods of preparing the anti-VISTA construct, pharmaceutical compositions containing the anti-VISTA construct, and methods of using the anti-VISTA construct or compositions.

Abstract: The present invention provides Wnt pathway agonists and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of diseases.

Abstract: Described herein are treatments and preventions for prurigo nodularis (PN), antibodies and pharmaceutical compositions for use in the treatment or prevention of PN, and uses of an anti-IL-31RA antibody (e.g., nemolizumab) in the manufacture of a medicament for the treatment or prevention of PN. Also described herein are biomarkers of PN and methods of altering or improving these biomarkers via treatments with an antibody that binds to IL-31RA (e.g., nemolizumab).

Abstract: Methods for treating moderate-to-severe atopic dermatitis of the hand and/or foot in a subject are provided. In one aspect, the methods comprise administering to the subject one or more doses of an interleukin-4 receptor (IL-4R) antagonist, such as an anti-IL-4R antibody or antigen-binding fragment thereof.

Abstract: Provided are antibodies or fragment thereof having binding specificity to the human chemokine (C-C motif) receptor 8 (CCR8) protein. These antibodies are capable of binding to CCR8 at high affinity and can mediate antibody-dependent cellular cytotoxicity (ADCC).

Abstract: The disclosure provides TNF-like ligand 1a (TL1a)-binding proteins comprising an antigen binding domain of an antibody which binds specifically to TL1a and inhibits interaction of TL1a and Death Receptor 3 (DR3) and which does not inhibit the interaction of TL1a and Decoy Receptor 3 (DcR3). The disclosure also provides uses of the TL1a-binding proteins.

Abstract: Human antibodies immunospecific for human CD27 are capable of blocking CD27 binding to its ligand CD70 and neutralizing bioactivity of CD27 including, but not limited to, CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by CD70, and the production of soluble mediators from T and B-cells. The antibodies are useful in diagnosing or treating CD27 activity associated diseases and conditions.

Abstract: The present invention provides methods and compositions comprising a particle comprising at least two different targeting agents that each bind a different protein receptor on a T cell surface.

Abstract: Anti-DR5 family member antibodies and bispecific antibodies comprising one or more anti-DR5 family member antibodies are disclosed. These antibodies can be used to trigger cell death on DR5 positive cells.

Abstract: Provided herein are polypeptides that bind to a transferrin receptor, methods of generating such polypeptides, and methods of using the polypeptides to target a composition to a transferrin receptor-expressing cell.

Abstract: Provided herein are heavy chain constant regions (referred to as “modified heavy chain constant regions”), or functionally equivalent fragments thereof, that enhance biological properties of antibodies relative to the same antibodies in unmodified form. An exemplary modified heavy chain constant region includes an IgG2 hinge and three constant domains (i.e., CH1, CH2, and CH3 domains), wherein one or more of the constant region domains are of a non-IgG2 isotype (e.g., IgG1, IgG3 or IgG4). The heavy chain constant region may comprise wildtype human IgG domain sequences, or variants of these sequences. Also provided herein are methods for enhancing certain biological properties of antibodies that comprise a non-IgG2 hinge, such as internalization, agonism and antagonism, wherein the method comprises replacing the non-IgG2 hinge of the antibody with an IgG2 hinge.

Abstract: The invention generally relates to dosage regimes of anti-Cluster of Differentiation 73 (CD73) antibodies and/or anti-ectoenzyme ectonucleoside triphosphate diphosphohydrolase 2 (ENTPD2) antibodies, used in methods of treatment of cancer in a subject, as well as dosage regimes of anti-CD73 antibodies for use in treating cancer. The invention further generally relates to dosage regimes of combinations of agents, such as combinations comprising anti-CD73 antibodies and/or anti-ENTPD2 antibodies and at least one or more of a PD-1 inhibitor, and an adenosine A2AR antagonist.

Abstract: The present disclosure relates to an antibody binding specifically to CD55 or an antigen-binding fragment thereof; and a composition for preventing, treating and/or diagnosing cancer containing the same. The antibody of the present disclosure may be used as an effective therapeutic composition for various CD55-mediated diseases since it shows high binding ability and inhibitory effect for the CD55 protein which promotes tumor growth by inhibiting the complement immune mechanism. In addition, the antibody of the present disclosure may be usefully used as an effective therapeutic adjuvant that fundamentally removes drug resistance and remarkably improves therapeutic responsiveness in various diseases in which resistance to therapeutic agents with CDC (complement-dependent cytotoxicity) as a mechanism of action has been induced due to overexpression of CD55.

Abstract: Novel bispecific heterodimeric immunoglobulins that target both a component of the human CD47 antigen and human CD38 antigen are provided and in particular those comprising an anti-CD38 heavy chain variable region and a light chain variable region and an anti-CD47 heavy chain variable region and a light chain variable region. The present invention also relates to the use of this novel class of bispecific heterodimeric immunoglobulins to treat autoimmune and proliferative diseases and in particular cancers such as hematologic malignancies and solid tumors.

Abstract: Provided herein, in one aspect, are antibodies that immunospecifically bind to a human KIT antigen comprising the fourth and/or fifth extracellular Ig-like domains (that is, D4 and/or D5 domains), polynucleotides comprising nucleotide sequences encoding such antibodies, and expression vectors and host cells for producing such antibodies. The antibodies can inhibit KIT activity, such as ligand-induced receptor phosphorylation. Also provided herein are kits and pharmaceutical compositions comprising antibodies that specifically bind to a KIT antigen, as well as methods of treating or managing a KIT-mediated disorder or disease and methods of diagnosing a KIT-mediated disorder or disease using the antibodies described herein.

Abstract: Provided herein are antibodies and uses of the same.

Abstract: Methods are described for administering to a subject an anti-human platelet antigen (HPA)-1a monoclonal antibody. The methods include parenterally administering to the subject a pharmaceutical composition comprising an anti-HPA-1a monoclonal antibody in an amount of about 0.02 ng/mL to about 0.4 ng/mL, and/or an amount effective to achieve a maximum plasma concentration of the anti-HPA-1a monoclonal antibody of about 0.01 IU/mL to about 10 IU/mL in the subject.

Abstract: Provided is a regimen for administration of anti-HPA-1a antibodies to a pregnant subject for prevention of maternal alloimmunization with HPA-1a and fetal and neonatal alloimmune thrombocytopenia (FNAIT).

Abstract: Methods of inhibiting platelet activation and aggregation using peptide vaccines having binding specificity for the ? subunit of the (Na++K+)-ATPase are provided, along with methods for inhibiting or preventing or treating thrombosis without causing bleeding.

Abstract: An anti-MASP-2 antibody and use thereof. The anti-MASP-2 antibody specifically binds to a human MASP-2 protein at a KD value of about 2E-09M or less, and the anti-MASP-2 antibody specifically binds to a cynomolgus monkey MASP-2 protein at a KD value of about 2E-09M or less. Disclosed are an immunoconjugate containing the anti-MASP-2 antibody, a method for preparing the anti-MASP-2 antibody, and use of the anti-MASP-2 antibody.

Abstract: Provided is an isolated antigen-binding protein, wherein the drug is used for the treatment of tumor, and the isolated antigen-binding protein comprises a PD-L1 binding moiety and an OX40 binding moiety, wherein: the OX40 binding moiety is capable of recognizing and/or binding amino acid residues G70 and/or F71 in a human OX40 extracellular domain; and the PD-L1 binding moiety is capable of recognizing and/or binding amino acid residues I54, Y56, E58, Q66 and/or R113 in an N-terminal IgV domain of human PD-L1. Further provided is a use of the isolated antigen-binding protein in preparing a drug, wherein the drug is used for the treatment of tumors.

Abstract: The present invention relates to antibodies capable of binding human CD123 and capable of binding the V?2 chain of a human V?9V?2 T cell receptor. The invention further relates to pharmaceutical compositions comprising the antibodies of the invention and to uses of the antibodies of the invention for medical treatment.

Abstract: Provided herein are DLL3 binding proteins and DLL3 targeting multispecific proteins (e.g., DLL3 targeting trispecific protein) comprising a domain binding to CD3, a half-life extension domain, and a domain binding to DLL3 (such as a DLL3 binding protein as provided herein). Also provided are pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such DLL3 binding proteins, DLL3 targeting trispecific proteins. Also disclosed are methods of using the disclosed DLL3 binding proteins, DLL3 targeting trispecific proteins in the prevention, and/or treatment diseases, conditions and disorders.

Abstract: A method for manufacturing a cellulose derivative includes a step of preparing a low crystalline cellulose having a degree of crystallinity of 70% or less and a step of derivatizing the low crystalline cellulose described above.

Abstract: According to an example aspect of the present invention, there is provided a method of producing cellulose carbamate in an aqueous phase. The method comprises the steps of a) providing a cellulose raw-material; b) providing urea; c) mixing cellulose and urea to provide a mixture; d) subjecting the mixture to a reduced pressure of no more than 350 mbar(a); e) heating the mixture to a temperature of 130 to 150° C. to subject cellulose to reaction with urea to form cellulose carbamate; f) releasing the pressure; and g) recovering the cellulose carbamate g) recovering the cellulose carbamate, and h) washing the cellulose carbamate with water to remove water soluble nitrogenous compounds wherein the water-soluble nitrogeneous compounds make up at the most 12%, preferably 6% or less, of the total weight of cellulose carbamate and water-soluble nitrogenous compounds.

Abstract: The invention relates to a method for producing a modified cationized polysaccharide. The method comprises preparing a reaction slurry by mixing of a starting material comprising a polysaccharide, preferably cellulose, and an alkaline liquid medium comprising an organic liquid, allowing the polysaccharide to interact with the alkaline liquid medium in the reaction slurry at a pre-treatment temperature under a pre-determined reaction time, and adjusting the temperature of the reaction slurry to modification temperature, which is less than the boiling point of the alkaline liquid medium. A cationizing agent and an alkylation agent, which comprises an epoxy group, are added to the reaction slurry at the modification temperature, and the polysaccharide is allowed to react with the alkylation agent and the cationizing agent, preferably under inert atmosphere, and obtaining a modified cationized polysaccharide product in solution form.

Abstract: The invention relates to a thermally modified starch produced via the acid route, characterized in that it has a free citrate content of less than 0.05% and a fixed citrate content of between 0.12 and 0.16% and/or a reduction of between 2 and 10° C. of the gelatinization temperature at RVA peak viscosity, and/or a sedimentation volume of between 15 and 35 mL.

Abstract: A process for preparing polyether-modified amino-functional polybutadienes involves a) reacting at least one polybutadiene (A) with at least one epoxidizing reagent (B) to give at least one epoxy-functional polybutadiene (C); b) reacting the at least one epoxy-functional polybutadiene (C) with at least one amino-functional compound (D) to give at least one hydroxy- and amino-functional polybutadiene (E); and c) reacting the at least one hydroxy- and amino-functional polybutadiene (E) with at least one epoxy-functional compound (F) to give at least one polyether-modified amino-functional polybutadiene (G). The polyether-modified amino-functional polybutadienes preparable by this process are also provided.

Abstract: The invention relates to a co-initiator comprising the aminobenzoate derivative according to Formula (I) and at least one ancillary amine, wherein the reactivity and solubility of said co-imitator in UV-curable resins is sufficiently high that the co-initiator can be used in UV radiation curing processes. Formula (I) wherein R1 and R2 independently represent methyl or ethyl groups; and j, k, l and m are independently 0 to 20.

Abstract: To provide a method for producing a perfluorinated compound, capable of easily producing a perfluorinated compound from which a high molecular weight polymer can be produced by a polymerization reaction, and a method for producing a fluorinated polymer using it.

Abstract: An optical resin composition of the present invention includes fluorine-containing resin and a refractive index modifier. The optical resin composition satisfies the following matter (a) or (b): (a) the refractive index modifier includes 95 mass % or more of a linear polymer (A) including repeating units based on a fluorine-containing ethylene-based monomer such that the number of the repeating units is 5, and a proportion of a content of the linear polymer (A) in the optical resin composition is 1 mass % or more and less than 15 mass %; (b) the refractive index modifier includes 95 mass % or more of a linear polymer (B) including repeating units based on a fluorine-containing ethylene-based monomer such that the number of the repeating units is 6, and a proportion of a content of the linear polymer (B) in the optical resin composition is 1 mass % or more and less than 13 mass %.

Abstract: A fluororesin including a residue unit of formula (1) and having a haze value equal to 2% or less of a heat-press molded product (thickness 1 mm) with a small haze value of a melt-molded product and a method for producing the same, Rf1, Rf2, Rf3 and Rf4 each independently represent one of the groups consisting of a fluorine atom, a linear perfluoroalkyl group having 1 to 7 carbon atoms, a branched perfluoroalkyl group having 3 to 7 carbon atoms, and a cyclic perfluoroalkyl group having 3 to 7 carbon atoms, the perfluoroalkyl group may have an ethereal oxygen atom, Rf1, Rf2, Rf3 and Rf4 may be linked to each other to form a ring having 4 or more and 8 or less carbon atoms, and the ring may include an ethereal oxygen atom.

Abstract: The present invention provides a polyvinyl alcohol resin with which a polyvinyl acetal resin having a controlled particle size and forming less lumps during dissolution to exhibit excellent solubility can be produced. Provided is a polyvinyl alcohol resin containing: methyl acetate; a vinyl alcohol unit; and a vinyl acetate unit, the methyl acetate being contained in an amount of 0.05 to 3% by weight, the vinyl alcohol unit being contained in an amount of 80 to 99.5 mol %, the vinyl acetate unit having a mean chain length LA of 1 to 4.5, the vinyl alcohol unit having a mean chain length LO of 1 to 30.

Abstract: Disclosed herein are compositions to use in biofouling-resistant coatings, biofouling-resistant coatings, methods of making biofouling-resistant coatings, biofouling-resistant devices, and methods of making biofouling-resistant devices.

Abstract: A photocurable liquid composition capable of forming a cured product in which localization of metal oxide nanoparticles is suppressed, a cured product of the photocurable liquid composition, and a method for producing a cured product using the photocurable liquid composition. As a nitrogen-containing compound, at least one of an amine compound having a specific structure and an imine compound having specific structure is added to the photocurable liquid composition including the photopolymerizable monomer, metal oxide nanoparticles, and a photopolymerization initiator.

Abstract: This disclosure relates to a curable composition comprising (a) at least one light polymerizable liquid; (b) at least one epoxy precursor dissolved in component (a); and (c) at least one photoinitiator; wherein the curable composition exhibits no more than 15% increase in viscosity at 25° C. after 7 days at room temperature.

Abstract: Embodiments in accordance with the present invention encompass copolymers, terpolymers and tetrapolymers of a variety of polycycloolefinic monomers at least one of which monomer contains an unpolymerized acrylate group. In further aspect of this invention there is provided an embodiment encompassing compositions containing the polymers of this invention, a crosslinker, a free radical initiator, a tackifier and one or more suitable additives. There is also provided a mass polymerizable composition encompassing one or more polycycloolefinic monomers optionally containing a monomer with an acrylate group and/or a crosslinking agent containing multi-functional acrylate. The compositions of this invention can be formed into a variety of three-dimensional insulating articles upon exposure to suitable high temperature, such as for example films. The objects formed from the compositions of this invention exhibit hitherto unattainable low dielectric constant and low-loss properties, and very high thermal properties.

Abstract: The present disclosure provides a novel and practical alcohol and derivatives thereof which have more industrial value than existing petrochemical raw materials. The present disclosure further provides ethanol, characterized in that a peak in gas chromatography measured by gas chromatograph mass spectrometry (GC/MS) has at least one peak with a retention time selected from (A) a peak of 5 minutes 25 seconds to 5 minutes 35 seconds and two peaks of 2 minutes 55 seconds to 3 minutes 5 seconds; (B) a peak of 12 minutes 30 seconds to 12 minutes 40 seconds; (C) a peak of 6 minutes 36 seconds to 6 minutes 45 seconds; and (D) a peak of 15 minutes 00 seconds to 15 minutes 15 seconds.

Abstract: The present invention relates to a process for manufacturing a biopolymer chemically modified with a functional group selected from a carbon-carbon double bond, a carbon-carbon triple bond and a nitrogen-nitrogen triple bond, wherein following chemical modification in an aqueous solution, the biopolymer is precipitated in an organic solvent, filtered and dried, and the organic solvent is recovered by distillation. A biopolymer chemically modified with a functional group selected from a carbon-carbon double bond, a carbon-carbon triple bond and a nitrogen-nitrogen triple bond obtained by said manufacturing process, and a hydrogel thereof are also provided.

Abstract: An unsaturated polyester resin composition contains an unsaturated polyester, a vinyl ester, a polymerizable monomer, and an aluminum hydroxide. The vinyl ester is a reaction product of an epoxy resin and an unsaturated monobasic acid. The vinyl ester is blended in a predetermined ratio to the unsaturated polyester. The aluminum hydroxide is blended in a predetermined ratio to the vinyl ester.

Abstract: The disclosure relates to a styrenic block copolymer (SBC) having at least a triblock, and a diblock structure with a diblock content of up to 50 wt. %. The SBC is suitable for film applications requiring soft stretch properties even without adding oil, pressure sensitive adhesive applications, photocurable (photopolymerizable) printing plates, etc. Additional components can be added to the SBC, accordingly, forming the end-use (application) composition.

Abstract: A composition for forming a polyurethane foam is provided using polyol having a total unsaturation less than 0.04 meq/g, methylene diphenyl diisocyanate (MDI), and epoxidized soybean oil. The epoxidized soybean oil may comprise greater than about 5% by weight of the composition. A method for forming polyurethane foam using the aforementioned composition is also provided.

Abstract: A polyalkyleneoxy polyol (P) has an average nominal functionality in the range of 2 to 8; a hydroxy number in the range of 10 to 500 mg KOH/g measured according to ASTM method D4272; and a weight average molecular weight in the range of 500 to 25,000 measured using GPC with polystyrene standard and tetrahydrofuran as solvent. The polyol (P) contains ethyleneoxy in an amount in the range of 50 to 95 wt. %, based on the overall weight of the polyol (P).

Abstract: A curing resin composition including (A) a cyanate ester resin, (B) an epoxy resin, (C) an active hydrogen-containing amine latent curing agent, and (D) an ion scavenger. The cyanate ester resin (A) is preferably at least one of a compound of formula (1) below, a compound of formula (2) below, and a polymer of at least one of these compounds (1) and (2). NC—O-A1-Y1-A2-O—CN??(1) wherein the symbols are as defined in the description. wherein the symbols are as defined in the description.

Abstract: Disclosed is a curable resin composition containing: (A) a cyanate ester resin; (B) an epoxy resin essentially including at least a 4-amino-3-methylphenol-type epoxy resin; and (C) a latent curing agent. Preferably, the cyanate ester resin (A) is at least one selected from the group consisting of compounds represented by formula (1) below, compounds represented by formula (2) below, and at least one of polymer of these compounds. Formula (1): NC—O-A1-Y1-A2-O—CN (See the Description for the symbols in the formula). Formula (2): (See the Description for the symbols in the formula).

Abstract: An epoxy resin composition contains a curing agent A, a curing agent B, a curing agent C, an epoxy resin D, an epoxy resin E, and resin particles F, wherein the curing agent A is an aromatic polyamine having a substituent selected from an alkyl group, an aromatic group, and a halogen group at each of two ortho positions of an amino group, the curing agent B is an aromatic polyamine that is liquid at 25° C., and the curing agent C is an aromatic polyamine having only one electron donating substituent or no substituent at an ortho position of an amino group, the epoxy resin D is constituted by an epoxy resin which is composed of a monomer containing 4 or more glycidyl groups, and the epoxy resin E is constituted by an epoxy resin which is composed of a monomer containing 2 or 3 glycidyl groups.

Abstract: Embodiments of the invention relate to a novel class of polymers with superior mechanical properties and chemical stability, as compared to known polymers. These polymers are particularly well suited for use in anion exchange membranes (AEMs), including those employed in fuel cells. Novel methods for the manufacture of these polymers are also described.

Abstract: A polylactic acid resin composition contains a polyactic acid resin satisfying: (1) the polylactic acid resin has a melt viscosity of 2,000 to 40,000 Pa·s at 190 degrees C.; and (2) the polylactic acid resin has a region of a weight average molecular weight Mw of 1,000 or less of 10 or less percent and a region of a weight average molecular weight Mw of 500,000 or more of 20 or more percent in a region of a weight average molecular weight Mw of 100 or more of a molecular weight distribution as measured by gel permeation chromatography, wherein the polylactic acid resin accounts for 90 or more percent of the polylactic acid resin composition.

Abstract: A composition with improved adhesive and sealant properties comprises a) a pre-polymer comprising a polymeric unit of the general formula (-A-B-)n, wherein A represents a substituted or un-substituted ester, B represents a substituted or un-substituted acid ester comprising at least two acid ester functionalities, and n represents an integer greater than 1; wherein the content of grafted anhydride in the composition is less than 0.05 mol/mol of polyacid.